The clinical scenario describes Barrett's esophagus, a classic example of metaplasia where stratified squamous epithelium of the esophagus is replaced by columnar epithelium (intestinal-type with goblet cells) in response to chronic acid reflux.
| Statement | Correctness | Rationale |
|---|---|---|
| Metaplastic epithelium more resistant to acid | ✓ Correct | Columnar epithelium is better adapted to acidic environment than squamous epithelium; this is the adaptive advantage |
| Reversible in early stages | ✓ Correct | Early metaplasia can regress if the causative stimulus (reflux) is eliminated; hence it is reversible |
| Lower malignant potential, no surveillance needed | ✗ WRONG | Barrett's esophagus carries increased risk of adenocarcinoma (30–40× higher than general population); surveillance is mandatory |
| Chronic inflammation drives transformation | ✓ Correct | Repeated injury-repair cycles activate transcription factors (CDX2, GATA6) that reprogram squamous cells to columnar phenotype |
Metaplasia ≠ Dysplasia. Metaplasia is reversible adaptive change; dysplasia is irreversible pre-malignant change. However, Barrett's esophagus (metaplasia) carries significant cancer risk and requires endoscopic surveillance every 2–3 years.
Barrett's esophagus progression pathway:
The presence of intestinal metaplasia with goblet cells (not just columnar epithelium) is required for the diagnosis of Barrett's esophagus. This is why surveillance is needed — dysplasia can develop within metaplastic mucosa without obvious clinical warning.
Metaplasia always regresses — While early metaplasia may regress if stimulus is removed, Barrett's esophagus often persists and progresses despite acid suppression therapy. The malignant potential is real and surveillance is non-negotiable.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
Daily MCQs, study tips, and topper strategies on Telegram.
Join on Telegram →